Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...

Chronic Obstructive Pulmonary Disease II: Emphysema

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Atypical Pneumonia

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Importance of Early Mycological Clearance of Uncomplicated Candidaemia and Its Implications for Clinical Practice.

Mycoses·2025

Same author

Molecular diagnostics in cancer patients with suspected respiratory mold infections.

Journal of clinical microbiology·2025

Same author

Costs and resource utilization patterns in surgical site infections: a pre-COVID-19 perspective from France, Germany, Spain, and the UK.

The Journal of hospital infection·2024

Same author

How to diagnose and treat a patient without human immunodeficiency virus infection having Pneumocystis jirovecii pneumonia?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2023

Same author

Liposomal amphotericin B-the future.

The Journal of antimicrobial chemotherapy·2022

Same author

SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report.

Journal of investigational allergology & clinical immunology·2022

Search research articles

Related Experiment Video

Updated: May 5, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Chronic pulmonary aspergillosis.

K E Schweer¹, C Bangard, K Hekmat

¹1st Department of Internal Medicine, Center for Clinical Studies II in Infectious Diseases, University Hospital Cologne, Cologne, Germany.

|December 5, 2013

Summary

This summary is machine-generated.

Chronic pulmonary aspergillosis (CPA) is a serious lung disease affecting those with underlying conditions. Management involves diagnostics like CT scans and antifungals, but Aspergillus resistance is a growing concern.

Keywords:

Chronic cavitary pulmonary aspergillosis chronic fibrosing pulmonary aspergillosis chronic necrotising pulmonary aspergillosis complex aspergilloma semi-invasive aspergillosis subacute aspergillosis

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Confocal Laser Scanning Microscopy-Based Quantitative Analysis of Aspergillus fumigatus Conidia Distribution in Whole-Mount Optically Cleared Mouse Lung

Confocal Laser Scanning Microscopy-Based Quantitative Analysis of Aspergillus fumigatus Conidia Distribution in Whole-Mount Optically Cleared Mouse Lung

Published on: September 18, 2021

Related Experiment Videos

Last Updated: May 5, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Confocal Laser Scanning Microscopy-Based Quantitative Analysis of Aspergillus fumigatus Conidia Distribution in Whole-Mount Optically Cleared Mouse Lung

Confocal Laser Scanning Microscopy-Based Quantitative Analysis of Aspergillus fumigatus Conidia Distribution in Whole-Mount Optically Cleared Mouse Lung

Published on: September 18, 2021

Area of Science:

Pulmonology
Infectious Diseases
Medical Mycology

Background:

Chronic pulmonary aspergillosis (CPA) presents as a debilitating illness with persistent cough, dyspnea, and weight loss.
It commonly affects individuals with pre-existing lung conditions (e.g., COPD, mycobacteriosis) or immunosuppression (e.g., diabetes).
The exact epidemiology of CPA remains unclear, posing diagnostic and management challenges due to its chronic and relapsing nature.

Purpose of the Study:

To provide a comprehensive overview of the current literature on chronic pulmonary aspergillosis.
To propose a clinical working algorithm for the effective management of CPA.
To highlight diagnostic challenges and emerging treatment considerations, including antifungal resistance.

Main Methods:

Literature review of existing studies on CPA.
Analysis of diagnostic markers including serology and thoracic computed tomography (CT).
Evaluation of antifungal treatment efficacy and emerging resistance patterns.

Main Results:

Diagnostic tools include Aspergillus precipitins and CT findings (cavitation, pleural involvement, aspergilloma).
Various antifungals are effective, with azoles being common outpatient choices, though Aspergillus resistance is increasingly problematic.
Long-term prognosis is influenced by comorbidities, necessitating further research.

Conclusions:

CPA requires careful management due to its complex nature and potential for antifungal resistance.
Thoracic CT and serology are key diagnostic aids.
Prospective studies are crucial for advancing our understanding and improving CPA patient outcomes.